Compare SUPX & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUPX | ATAI |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | Singapore | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2024 | 2021 |
| Metric | SUPX | ATAI |
|---|---|---|
| Price | $17.74 | $4.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 430.2K | ★ 3.6M |
| Earning Date | 10-24-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,596,575.00 | $3,018,000.00 |
| Revenue This Year | N/A | $943.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.88 | ★ 811.78 |
| 52 Week Low | $2.75 | $1.15 |
| 52 Week High | $76.50 | $6.75 |
| Indicator | SUPX | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 30.09 | 44.63 |
| Support Level | $16.03 | $4.25 |
| Resistance Level | $21.31 | $4.63 |
| Average True Range (ATR) | 3.84 | 0.22 |
| MACD | 0.18 | 0.08 |
| Stochastic Oscillator | 21.18 | 52.91 |
Super X AI Technology Ltd is an AI infrastructure solutions provider. Through its subsidiaries, SuperX offers a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, High-Voltage Direct Current (HVDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. The Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.